Annals of Medicine and Surgery · Nov 4, 2026

Early finerenone and sodium-glucose cotransporter 2 inhibitor therapy in diabetic kidney disease: a risk-readiness-reassessment framework

By Ejaz RA, Khan K

Diabetic kidney disease carries residual cardiorenal risk despite renin-angiotensin system blockade. Combination effect of Finerenone and Empagliflozin in participants with chronic kidney disease and type 2 diabetes using a urinary albumin-to-creatinine ratio Endpoint showed that simultaneous finerenone and the sodium-glucose cotransporter 2 inhibitor empagliflozin reduced urinary albumin-to-creatinine ratio by 52%, compared with 32% with finerenone and 29% with empagliflozin. Adverse events leading to discontinuation were uncommon. However, the trial used a surrogate endpoint, was limited to 180 days of follow-up, and excluded patients with estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m ² or potassium above 4.8 mmol/L. This editorial examines the implications of these limitations for patient selection, timing, and safety monitoring, and proposes a risk-readiness-reassessment framework. Cardiorenal risk determines the urgency of combination therapy; readiness determines whether treatment should be initiated simultaneously or staged over 2–4 weeks; and reassessment distinguishes expected changes from clinically important harm. Simultaneous initiation may be reasonable when potassium, eGFR, blood pressure, volume status, and monitoring access are favorable. Rapid staged initiation may be preferable when these factors create diagnostic or safety uncertainty. The framework requires prospective validation. The objective should be timely, sustainable complementary therapy rather than same-day initiation in every eligible patient.

doi.org/10.1097/ms9.0000000000005800 Open access Interventions